We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

62 hedge funds and large institutions have $73.7M invested in Ovid Therapeutics in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 22 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

480% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 5

340% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 5

177% more capital invested

Capital invested by funds: $26.6M → $73.7M (+$47.1M)

63% more funds holding

Funds holding: 38 → 62 (+24)

15.93% more ownership

Funds ownership: 21.21% → 37.15% (+16%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
62
Holders Change
+24
Holders Change %
+63.16%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
29
Increased
22
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$9.12M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.58M
3
Axa
Axa
France
+$2.74M
4
Citigroup
Citigroup
New York
+$1.58M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.57M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$5.01M
2
Marshall Wace
Marshall Wace
United Kingdom
-$59K
3
MWNA
Marshall Wace North America
New York
-$41K
4
WG
Winton Group
United Kingdom
-$34K
5
Northern Trust
Northern Trust
Illinois
-$24.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
1
Consonance Capital Management
New York
$12M +$9.12M +2,888,888 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$8.65M +$6.58M +2,084,900 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$6.18M +$1.34M +423,961 +40%
Renaissance Technologies
4
Renaissance Technologies
New York
$4.5M +$1.57M +497,984 +85%
Axa
5
Axa
France
$3.6M +$2.74M +867,602 New
CA
6
CHI Advisors
New York
$3.5M +$368K +116,671 +16%
BI
7
BVF Inc
California
$3.05M -$5.01M -1,586,935 -68%
Citigroup
8
Citigroup
New York
$2.08M +$1.58M +499,976 +33,646%
Wells Fargo
9
Wells Fargo
California
$1.97M +$164K +51,933 +12%
BlackRock
10
BlackRock
New York
$1.87M +$998K +315,948 +234%
TCM
11
Tekla Capital Management
Massachusetts
$1.55M – – –
IC
12
Ikarian Capital
Texas
$1.45M +$1.11M +350,000 New
GPCM
13
Granite Point Capital Management
Massachusetts
$1.45M – – –
Morgan Stanley
14
Morgan Stanley
New York
$1.42M +$893K +282,933 +478%
Millennium Management
15
Millennium Management
New York
$1.33M +$691K +218,876 +217%
PIM
16
Platinum Investment Management
Australia
$1.27M +$557K +176,546 +136%
AC
17
AWH Capital
Texas
$1.27M +$142K +45,000 +17%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.19M +$192K +60,887 +27%
EI
19
EAM Investors
California
$1.18M +$249K +78,947 +38%
CS
20
Credit Suisse
Switzerland
$1.13M +$859K +272,164 New
SCM
21
Sio Capital Management
New York
$1.1M +$835K +264,581 New
Qube Research & Technologies (QRT)
22
Qube Research & Technologies (QRT)
United Kingdom
$1.04M +$793K +251,262 New
BCM
23
Bridgeway Capital Management
Texas
$1.01M +$102K +32,400 +15%
Acadian Asset Management
24
Acadian Asset Management
Massachusetts
$947K -$13.8K -4,378 -2%
JP Morgan Chase
25
JP Morgan Chase
New York
$912K +$386K +122,336 +126%
1
2 3

OVID Hedge Fund Activity: Q4 2019 in Review

62 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2019, worth a combined $73.7M — up 177% from $26.6M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new OVID positions and 5 closed out — a net gain of 24 holders — while 22 added to existing stakes and 5 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $9.12M. The largest seller was BVF Inc, cutting an estimated $5.01M.

  • 62 institutional investors held Ovid Therapeutics (OVID) as of Q4 2019, up from 38 in Q3 2019.
  • Funds reported $73.7M of Ovid Therapeutics stock for Q4 2019, up 177% quarter-over-quarter.
  • 29 funds opened new Ovid Therapeutics positions in Q4 2019 and 5 closed out, a net change of +24 holders.
  • The largest Ovid Therapeutics buyer in Q4 2019 was Consonance Capital Management, an estimated $9.12M added.
  • The largest Ovid Therapeutics seller in Q4 2019 was BVF Inc, an estimated $5.01M sold.

Based on aggregated 13F filings for Q4 2019.